Recent evidences show up the dual role of NOX1/NOX4 pharmacological inhibitors in decreasing both the apparition of fibrogenic markers and hepatocyte apoptosis in vivo (114, 116), highlighting the relevance of NOX1 and NOX4 in liver fibrosis and opening new perspectives for its treatment. This evidence concerns the gene NOX1 and Hepatic fibrosis.